Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer
QIMC Reports Elevated Clean Hydrogen in First 100 Metres of DDH-26-04 at Bennett Hill, Nova Scotia, Including Four Analyzer-Saturating Readings Within a 9-Metre Interval
Cespira, the Joint Venture between Westport and Volvo Group, Signs Agreement with Volvo Group to Complete Hydrogen-Fueled Engine Development
